以岭药业(002603.SZ)子公司拟斥50.34亿元投建现代中药产业化项目
格隆汇11月15日丨以岭药业(002603.SZ)公布，2019年11月15日，公司第六届董事会第二十七次会议审议通过了《关于全资子公司投资建设现代中药产业化项目的议案》。公司拟以衡水以岭为项目实施主体，投资建设“衡水以岭药业有限公司现代中药产业化项目”，该项目生产产品主要包括中药配方颗粒、中药片剂及保健品。项目计划投资总额人民币约50.34亿元，项目资金来源为衡水以岭自筹资金。该项目计划已取得河北省企业投资项目备案证明。
公司拟通过衡水以岭项目建设，建立符合要求的生产基地，扩大中药配方颗粒、中药片剂、保健品的生产规模和生产能力，推动公司中药板块和大健康板块发展，进一步增强公司的市场竞争力。
项目名称：衡水以岭药业有限公司现代中药产业化项目；项目具体实施内容：项目总占地面积约110.74万平方米(合1661.16亩)，总建筑面积约121.66万平方米，主要建设内容包括饮片加工车间、提取车间、制剂车间、保健品车间、榨油车间及锅炉房、仓储等生产及辅助设施。项目建设达产后将实现年产中药饮片4200吨、配方颗粒4500吨、中药提取物4500吨、中药片剂30亿片及中药保健品软胶囊10亿粒、保健食品500吨、保健饮料1000吨生产能力，为未来公司发展和市场扩张打下良好的基础。
项目总投资估算为50.34亿元。其中建设投资约48.32万元，铺底流动资金2.03亿元。项目建设期3年，建设投资计划在建设期内投入，投入比例为第一年40%，第二年40%，第三年20%。
项目建成达产后，预计可实现年销售收入约57.70亿元，净利润约26.90亿元，投资回收期约4.96年(上述经济效益预测并不代表公司对未来盈利的保证，能否实现取决于市场状况的变化、经营团队管理水平等多种因素的影响，存在着一定的不确定性，请投资者注意风险)。
项目建设是出于公司未来发展的战略性考虑，符合公司做大做强主营业务的发展战略，既有利于进一步完善公司中药、健康产业生产基地的战略布局，扩大中药片剂、中药饮片、保健品产能，又可为公司未来发展中药配方颗粒、中药提取物业务做好产能储备，从而达到优化公司产品结构的目的，对于提升公司核心竞争力具有重要意义。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
